Key Points
- Rafael Amado sold 10,787 ZLAB shares on Dec. 31 at an average price of $17.43 for about $188,017, cutting his holding by 17.07% to 52,391 shares (SEC Form 4 filed).
- Zai Lab shares trade near $17.33 after a quarter that missed revenue ($116.1M vs. $150.2M) and EPS (‑$0.33 vs. ‑$0.28), with negative margins and an expected FY EPS of ‑2.58, though analysts' consensus remains a "Moderate Buy" with a $56.35 price target.
Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB - Get Free Report) insider Rafael Amado sold 10,787 shares of the stock in a transaction that occurred on Wednesday, December 31st. The shares were sold at an average price of $17.43, for a total value of $188,017.41. Following the completion of the sale, the insider directly owned 52,391 shares of the company's stock, valued at $913,175.13. The trade was a 17.07% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink.
Zai Lab Price Performance
Shares of Zai Lab stock opened at $17.33 on Friday. The firm's fifty day simple moving average is $20.37 and its 200-day simple moving average is $29.21. Zai Lab Limited Unsponsored ADR has a 12 month low of $16.82 and a 12 month high of $44.34. The stock has a market capitalization of $1.94 billion, a price-to-earnings ratio of -8.89 and a beta of 0.83.
Zai Lab (NASDAQ:ZLAB - Get Free Report) last issued its quarterly earnings results on Thursday, November 6th. The company reported ($0.33) earnings per share for the quarter, missing analysts' consensus estimates of ($0.28) by ($0.05). The business had revenue of $116.10 million for the quarter, compared to analyst estimates of $150.24 million. Zai Lab had a negative return on equity of 25.83% and a negative net margin of 46.83%. Analysts anticipate that Zai Lab Limited Unsponsored ADR will post -2.58 earnings per share for the current year.
Wall Street Analysts Forecast Growth
Separately, Weiss Ratings restated a "sell (d-)" rating on shares of Zai Lab in a research report on Wednesday, October 8th. Six analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus price target of $56.35.
Get Our Latest Report on ZLAB
Institutional Inflows and Outflows
Several large investors have recently added to or reduced their stakes in ZLAB. SG Americas Securities LLC purchased a new stake in Zai Lab in the 3rd quarter valued at approximately $331,000. Royal Bank of Canada raised its stake in shares of Zai Lab by 214.3% during the 1st quarter. Royal Bank of Canada now owns 13,771 shares of the company's stock worth $498,000 after buying an additional 9,390 shares in the last quarter. Acadian Asset Management LLC acquired a new stake in shares of Zai Lab in the 1st quarter valued at approximately $1,073,000. Cubist Systematic Strategies LLC boosted its stake in shares of Zai Lab by 29.0% in the first quarter. Cubist Systematic Strategies LLC now owns 93,645 shares of the company's stock valued at $3,384,000 after buying an additional 21,026 shares in the last quarter. Finally, Raymond James Financial Inc. grew its holdings in Zai Lab by 219.6% during the first quarter. Raymond James Financial Inc. now owns 125,967 shares of the company's stock worth $4,552,000 after acquiring an additional 86,547 shares during the period. 41.65% of the stock is owned by hedge funds and other institutional investors.
About Zai Lab
(
Get Free Report)
Zai Lab Ltd (NASDAQ: ZLAB) is a biopharmaceutical company focused on the research, development, manufacturing and commercialization of innovative therapies. Headquartered in Shanghai, China, Zai Lab operates R&D centers in Asia and the United States and maintains commercial offices across Greater China, North America, Europe and Australia. The company's end-to-end platform encompasses discovery biology, translational development, clinical research and global supply chain management.
The company's marketed portfolio is anchored by Brukinsa (zanubrutinib), a next-generation Bruton's tyrosine kinase inhibitor approved for several B-cell malignancies.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
